421 related articles for article (PubMed ID: 32997401)
1. Hyperprogression: A novel response pattern under immunotherapy.
Han XJ; Alu A; Xiao YN; Wei YQ; Wei XW
Clin Transl Med; 2020 Sep; 10(5):e167. PubMed ID: 32997401
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression and hyperprogression after checkpoint blockade.
Wang Q; Gao J; Wu X
Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogression after immunotherapy.
Abbas W; Rao RR; Popli S
South Asian J Cancer; 2019; 8(4):244-246. PubMed ID: 31807489
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
5. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence.
Zheng J; Zhou X; Fu Y; Chen Q
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831655
[TBL] [Abstract][Full Text] [Related]
7. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
8. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogression as a distinct outcome after immunotherapy.
Fuentes-Antrás J; Provencio M; Díaz-Rubio E
Cancer Treat Rev; 2018 Nov; 70():16-21. PubMed ID: 30053725
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
Zhou L; Zhang M; Li R; Xue J; Lu Y
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3269-3279. PubMed ID: 32857178
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.
Lin M; Vanneste BGL; Yu Q; Chen Z; Peng J; Cai X
Transl Lung Cancer Res; 2021 Jul; 10(7):3276-3291. PubMed ID: 34430364
[TBL] [Abstract][Full Text] [Related]
12. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive disease: recognizing a novel pattern to improve patient management.
Champiat S; Ferrara R; Massard C; Besse B; Marabelle A; Soria JC; Ferté C
Nat Rev Clin Oncol; 2018 Dec; 15(12):748-762. PubMed ID: 30361681
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.
Kocikowski M; Dziubek K; Parys M
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32230745
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.
Zhao LP; Hu JH; Hu D; Wang HJ; Huang CG; Luo RH; Zhou ZH; Huang XY; Xie T; Lou JS
Biomed Pharmacother; 2022 Jun; 150():112949. PubMed ID: 35447545
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
Li Y; Wang P; Xu J; Shi X; Yin T; Teng F
Oncoimmunology; 2024; 13(1):2312628. PubMed ID: 38343749
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab.
Sahin I; George A; Zhang S; Huntington KE; Ordulu Z; Zhou L; El-Deiry WS
Oncotarget; 2021 Oct; 12(21):2131-2146. PubMed ID: 34676046
[TBL] [Abstract][Full Text] [Related]
18. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
[TBL] [Abstract][Full Text] [Related]
19. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Kang DH; Chung C; Sun P; Lee DH; Lee SI; Park D; Koh JS; Kim Y; Yi HS; Lee JE
Cancer Immunol Immunother; 2022 Mar; 71(3):579-588. PubMed ID: 34278517
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics.
Singla R; Gupta A; Batra U; Chaturvedi A; Rao A; Jajodia A
Indian J Radiol Imaging; 2021 Apr; 31(2):345-349. PubMed ID: 34556917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
